Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Mars orbiter sees 'butterfly' crater spread its wings on the Red Planet - 2DEA seizes 1.7 million counterfeit fentanyl pills in Colorado storage unit
- 35 Fundamental Ways to employ a Criminal Legal counselor
- 4Land Rover Just Unveiled Its Dakar Rally Defender
- 5Fireballs and a full moon. Here’s how to see two celestial events this week
- Flu surges across U.S. as doctor visits reach highest level since 1997
- International issues on the agenda as Frances's Macron visits China
- Step by step instructions to Figure out the Natural Effect of 5G Pinnacles
- Make your choice for the PS5 game that you love playing with companions!
- 10 Picturesque Campgrounds That Will Raise Your Outside Involvement with American
- Spots To Go Birdwatching All over the Planet
- Audits of Espresso Types: Which Mix Is for You?
- Green Inflections: A Manual for Inside Plants
- Mechanical Sidekick d: A Survey of \Elements and Execution d\ Cell phone
